Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib

Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
Country
Agency
Status
Link
Details of use
Austria
LBI-HTA
2017
LINK
National adaptation, Made no changes to the information used, added recommendations
Croatia
AAZ
2017
A summary of the report was prepared in the national language, as well as assessment elements B0001 and A0020, with links to the full report on English language. Upon Croatian decision makers request on this topic, the report will be updated if needed and local information will be added (i.e., epidemiological information such as patient numbers; the technologies available in Croatia, information about costs…), including recommendations.
Czech Republic
SUKL
2019
National adaptation. Added local information.
Denmark
Danish Medicines Council
2018
LINK
Used for background information.
Finland
HILA
2018
Read the assessment for background information.
France
HAS
Work completed in 2018
LINK
The national report structure is partly based on the REA, especially for the EFF and SAF parts. Most of the references used in the TEC and CUR parts are also in the national report. Final REA was transmitted to the HTA committee members before the national assessment. Cited in the national report as background or additional information.
Italy
AIFA
2017
Efficacy and safety information used as supportive information in national report. Cited in the national report as background or additional information
Portugal
INFARMED
2017
LINK
National adaptation, translated some sections of the REA for use in national report and added recommendations.
Spain
AEMPS
2017
LINK
Cited in report as background or additional information.
UK (Scotland)
SMC
2018
LINK
Used for background information
Croatia
AAZ
2017
A summary of the report was prepared in the national language, as well as assessment elements B0001 and A0020, with links to the full report on English language. Upon Croatian decision makers request on this topic, the report will be updated if needed and local information will be added (i.e., epidemiological information such as patient numbers; the technologies available in Croatia, information about costs…), including recommendations.
Spain
AETSA
2018
LINK
A summary of this assessment in Spanish together with the full English report has been published on AETSA’s website for dissemination. In addition, the report has been distributed to regional decision-makers and oncologists
UK
NICE
2017
LINK
Used as background information to check that similar issues were being identified in national assessment. In addition, EUnetHTA reports are indexed in NHS Evidence, a public database which provides access to selected sources of evidence in health, social case and public health.
Poland
AOTMiT
2018
LINK
Cited in the national report as background or additional information. Updated evidence, added local information and budget impact and cost effectiveness analysis.
Spain
OSTEBA
2017
Disseminated to oncologists and relevant decision makers (managers of the Pharmacy section of the Basque Health Service).
Findland
HILA
2018
Read the assessment for background information.
Norway
NOMA
2018
National adaptation. Added local information.
Slovakia
UNIBA
2018
National adaptation. Added local information.
Czech Republic
SUKL
2019
National adaptation. Added local information.
This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.